5-(3,3-dimethylbut-1-ynyl)-3-((1R,6S,7r)-N-isopropylbicyclo[4.1.0]heptane-7-carboxamido)thiophene-2-carboxylic acid | 1485468-99-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 5-(3,3-dimethylbut-1-ynyl)-3-((1R,6S,7r)-N-isopropylbicyclo[4.1.0]heptane-7-carboxamido)thiophene-2-carboxylic acid
• CAS: 1485468-99-2
• 化学式: C₂₂H₂₉NO₃S
• 分子量: 387.543
• InChiKey: FAQCAJLZWJZMPB-VQFNDLOPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.02
• 重原子数：
  27.0
• 可旋转键数：
  4.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  57.61
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为产物：
  描述：

  methyl 3-amino-5-(3,3-dimethylbut-1-ynyl)thiophene-2-carboxylate 在 甲醇 、 4-二甲氨基吡啶 、 lithium hydroxide monohydrate 、 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 34.5h， 生成 5-(3,3-dimethylbut-1-ynyl)-3-((1R,6S,7r)-N-isopropylbicyclo[4.1.0]heptane-7-carboxamido)thiophene-2-carboxylic acid
  参考文献：
  名称：

  Discovery of GS-9669, a Thumb Site II Non-Nucleoside Inhibitor of NS5B for the Treatment of Genotype 1 Chronic Hepatitis C Infection

  摘要：

  Investigation of thiophene-2-carboxylic acid HCV NS5B site II inhibitors, guided by measurement of cell culture medium binding, revealed the structure activity relationships for intrinsic cellular potency. The pharmacokinetic profile was enhanced through incorporation of heterocyclic ethers on the N-alkyl substituent. Hydroxyl groups were incorporated to modulate protein binding. Intrinsic potency was further improved through enantiospecific introduction of an olefin in the N-acyl motif, resulting in the discovery of the phase 2 clinical candidate GS-9669. The unexpected activity of this compound against the clinically relevant NS5B M423T mutant, relative to the wild type, was shown to arise from both the N-alkyl substituent and the N-acyl group.

  DOI：

  10.1021/jm401420j

文献信息

• Discovery of GS-9669, a Thumb Site II Non-Nucleoside Inhibitor of NS5B for the Treatment of Genotype 1 Chronic Hepatitis C Infection
  作者：Scott E. Lazerwith、Willard Lew、Jennifer Zhang、Philip Morganelli、Qi Liu、Eda Canales、Michael O. Clarke、Edward Doerffler、Daniel Byun、Michael Mertzman、Hong Ye、Lee Chong、Lianhong Xu、Todd Appleby、Xiaowu Chen、Martijn Fenaux、Ahmad Hashash、Stephanie A. Leavitt、Eric Mabery、Mike Matles、Judy W. Mwangi、Yang Tian、Yu-Jen Lee、Jingyu Zhang、Christine Zhu、Bernard P. Murray、William J. Watkins

  DOI：10.1021/jm401420j

  日期：2014.3.13

  Investigation of thiophene-2-carboxylic acid HCV NS5B site II inhibitors, guided by measurement of cell culture medium binding, revealed the structure activity relationships for intrinsic cellular potency. The pharmacokinetic profile was enhanced through incorporation of heterocyclic ethers on the N-alkyl substituent. Hydroxyl groups were incorporated to modulate protein binding. Intrinsic potency was further improved through enantiospecific introduction of an olefin in the N-acyl motif, resulting in the discovery of the phase 2 clinical candidate GS-9669. The unexpected activity of this compound against the clinically relevant NS5B M423T mutant, relative to the wild type, was shown to arise from both the N-alkyl substituent and the N-acyl group.